Grab Holdings Ltd. vs Ionis Pharmaceuticals Inc. Common Stock — how do they compare? Grab Holdings Ltd. trades at $2.88 (market cap $12.19B), while Ionis Pharmaceuticals Inc. Common Stock trades at $42.5 (market cap $7.04B). The key difference: Grab Holdings Ltd. is the larger of the two by market cap, and Grab Holdings Ltd. is more actively traded (48,418,739 versus 2,977,440). Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Ionis Pharmaceuticals Inc. Common Stock for 0 Days on average.
| GRAB | IONS | |
|---|---|---|
Market Cap | $12.19B | $7.04B |
Volume | 48,418,739 | 2,977,440 |
Sector | Technology | Health |
52-Week High | $6.12 | $86.50 |
52-Week Low | $2.80 | $42.38 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $7.93B | $6.60B |
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $2.91, down 7.62% in the past 24 hours, with technical indicators showing bearish momentum. The company demonstrates strong fundamental improvement with revenue growing from $1.4B in 2022 to $3.37B in 2025 and achieving profitability with $268M net income. Recent developments include the $1.49B acquisition of Atome Financial and aggressive share repurchases, while management has shown confidence through significant insider buying.
GRAB presents a compelling turnaround story with accelerating revenue growth and recent profitability. The stock trades at reasonable valuations (P/E 27.09, P/S 3.65) with 92% analyst buy ratings. Key risks include integration challenges from the Atome acquisition and regional regulatory uncertainties in Southeast Asian markets.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →